[1] Peer D, Karp J M, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy[J]. Nature Nanotechnology, 2007, 2(12):751-760.
[2] Mann J. Natural products in cancer chemotherapy:Past, present and future[J]. Nature Reviews Cancer, 2002, 2(2):143-148.
[3] Petros R A, Desimone J M. Strategies in the design of nanoparticles for therapeutic applications[J]. Nature Reviews Drug Discovery, 2010, 9(8):615-627.
[4] Hassan S, Prakash G, Ozturk A, et al. Evolution and clinical translation of drug delivery nanomaterials[J]. Nano Today, 2017, 15:91-106.
[5] Veiga N, Goldsmith M, Granot Y, et al. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes[J]. Nature Communication, 2018, 9(1):4493.
[6] Szebeni J, Simberg D, González-Fernández Á, et al. Roadmap and strategy for overcoming infusion reactions to nanomedicines[J]. Nature Nanotechnology, 2018, doi:10.1038/s41565-018-0273-1.
[7] Liu Y, Jiang Y, Zhang M, et al. Modulating hypoxia via nanomaterials chemistry for efficient treatment of solid tumors[J]. Accounts of Chemical Research, 2018, 51(10):2502-2511.
[8] Anselmo A C, Mitragotri S. A review of clinical translation of inorganic nanoparticles[J]. AAPS Jounal, 2015, 17(5):1041-1054.
[9] Etheridge M L, Campbell S A, Erdman A G, et al. The big picture on nanomedicine:The state of investigational and approved nanomedicine products[J]. Nanomedicine, 2013, 9(1):1-14.
[10] Shi J, Kantoff P W, Wooster R, et al. Cancer nanomedicine:Progress, challenges and opportunities[J]. Nature Reviews Cancer, 2017, 17(1):20-37.
[11] Galic V L, Wright J D, Lewin S N, et al. Paclitaxel poliglumex for ovarian cancer[J]. Expert Opinion on Investigational Drugs, 2011, 20(6):813-821.
[12] Keefe S M, Hoffman-Censits J, Cohen R B, et al. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma:Results of an investigator-initiated phase I-Ⅱa clinical trial[J]. Annals of Oncology, 2016, 27(8):1579-1585.
[13] Tagami T, Ozeki T. Recent trends in clinical trials related to carrier-based drugs[J]. Journal of Pharmaceutical Sciences, 2017, 106(9):2219-2226.
[14] Duncan R, Sat Y N. Tumour targeting by enhanced permeability and retention (EPR) effect[J]. Annals of Oncology, 1998, 9:39-39.
[15] Torchilin V P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery[J]. Nature Reviews Drug Discovery, 2014, 13(11):813-827.
[16] Geretti E, Leonard S C, Dumont N, et al. Cyclophosphamidemediated tumor priming for enhanced delivery and antitumor activity of HER2-targeted liposomal doxorubicin (MM-302)[J]. Molecular Cancer Therapeutics, 2015, 14(9):2060-2071.
[17] Camp E R, Wang C, Little E C, et al. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy[J]. Cancer Gene Theray, 2013, 20(4):222-228.
[18] Tanaka T, Shiramoto S, Miyashita M, et al. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME)[J]. International Journal of Pharmaceutics, 2004, 277(1-2):39-61.
[19] Prabhakar U, Maeda H, Jain R K, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology[J]. Cancer Research, 2013, 73(8):2412-2417.
[20] Nehoff H, Parayath N N, Domanovitch L, et al. Nanomedicine for drug targeting:Strategies beyond the enhanced permeability and retention effect[J]. International Journal of Nanomedicine, 2014, 9:2539-2555.
[21] Du J Z, Li H J, Wang J. Tumor-acidity-cleavable maleic acid amide (TACMAA):A powerful tool for designing smart nanoparticles to overcome delivery barriers in cancer nanomedicine[J]. Accounts of Chemical Research, 2018, doi:10.1021/acs.accounts.8b00195.
[22] Zhang P, Wang J, Chen H, Zhao L, et al. Tumor microenvironment-responsive ultrasmall nanodrug generators with enhanced tumor delivery and penetration[J]. Journal of American Chemistry Society, 2018, doi:10.1021/jacs.8b09396.
[23] Zhou F Y, Feng B, Wang T T, et al. Programmed multiresponsive vesicles for enhanced tumor penetration and combination therapy of triple-negative breast cancer[J]. Advanced Functional Materials, 2017, 27(20):1606530.
[24] Guan X W, Guo Z P, Wang T H, et al. A pH-responsive detachable peg shielding strategy for gene delivery system in cancer therapy[J]. Biomacromolecules, 2017, 18(4):1342-1349.
[25] Wang D G, Wang T T, Liu J P, et al. Acid-activatable versatile micelleplexes for PD-L1 blockade enhanced cancer photodynamic immunotherapy[J]. Nano Letters, 2016, 16(9):5503-5513.
[26] Wang H X, Zuo Z Q, Du J Z, et al. Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines[J]. Nano Today, 2016, 11(2):133-144.
[27] Lee Y, Fukushima S, Bae Y, et al. A protein nanocarrier from charge-conversion polymer in response to endosomal pH[J]. Journal of the American Chemical Society, 2007, 129(17):5362-5364.
[28] Yuan Y Y, Mao C Q, Du X J, et al. Surface charge switchable nanoparticles based on zwitterionic polymer for enhanced drug delivery to tumor[J]. Advanced Materials, 2012, 24(40):5476-5480.
[29] Liu L H, Qiu W X, Zhang Y H, et al. A charge reversible self-delivery chimeric peptide with cell membrane-targeting properties for enhanced photodynamic therapy[J]. Advanced Functional Materials, 2017, 27(25):1700220.
[30] Bertrand N, Wu J, Xu X Y, et al. Cancer nanotechnology:The impact of passive and active targeting in the era of modern cancer biology[J]. Advanced Drug Delivery Reviews, 2014, 66:2-25.
[31] Li H J, Du J Z, Liu J, et al. Smart superstructures with ultrahigh ph-sensitivity for targeting acidic tumor microenvironment:Instantaneous size switching and improved tumor penetration[J]. ACS Nano, 2016, 10(7):6753-6761.
[32] Li H J, Du J Z, Du X J, et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy[J]. PNAS, 2016, 113(15):4164-4169.
[33] Chen J J, Ding J X, Wang Y C, et al. Sequentially responsive shell-stacked nanoparticles for deep penetration into solid tumors[J]. Advanced Materials, 2017, 29(32):201701170.
[34] Su J H, Sun H P, Meng Q S, et al. Long circulation redblood-cell-mimetic nanoparticles with peptide-enhanced tumor penetration for simultaneously inhibiting growth and lung metastasis of breast cancer[J]. Advanced Functional Materials, 2016, 26(8):1243-1252.
[35] Rao L, Bu L L, Xu J H, et al. Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance[J]. Small, 2015, 11(46):6225-6236.
[36] Mou X B, Ali Z S, Li S, et al. Applications of magnetic nanoparticles in targeted drug delivery system[J]. Journal of Nanoscience and Nanotechnology, 2015, 15(1):54-62.
[37] Yang Z, Fan W, Tang W, Shen Z, et al. Near-infrared semiconducting polymer brush and pH/GSH-responsive polyoxometalate cluster hybrid platform for enhanced tumor-specific phototheranostics[J]. Angewandte Chemie International Edition, 2018, 57(43):14101-14105.
[38] Costa DF, Mendes LP, Torchilin VP. The effect of low-and high-penetration light on localized cancer therapy[J]. Advanced Drug Delivery Review, 2018, doi:10.1016/j.addr.2018.09.004.
[39] Matera C, Gomila A M J, Camarero N, et al, Photoswitchable antimetabolite for targeted photoactivated chemotherapy[J]. Journal American Chemistry Society, 2018, doi:10.1021/jacs.8b08249.
[40] Ni J S, Zhang P, Jiang T, et al. Red/NIR-emissive benzo[d]imidazole-cored AIEgens:Facile molecular design for wavelength extending and in vivo tumor metabolic imaging[J]. Advanced Materials, 2018, doi:10.1002/adma.201805220.
[41] Liu Y, Bhattarai P, Dai Z, Chen X. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer[J]. Chemistry Society Review, 2018, doi:10.1039/c8cs00618k.
[42] Yu H J, Cui Z R, Yu P C, et al. pH and near-infrared lightresponsive micelles with hyperthermia-triggered tumor penetration reverse multidrug resistance in breast cancer[J]. Advanced Functional Materials, 2016, 12(2):461-461.
[43] Tay Z W, Chandrasekharan P, Chiu-Lam A, et al. Magnetic particle imaging-guided heating in vivo using gradient fields for arbitrary localization of magnetic hyperthermia therapy[J]. ACS Nano, 2018, 12(4):3699-3713.
[44] Pan X T, Bai L X, Wang H, et al. Metal-organic-frameworkderived carbon nanostructure augmented sonodynamic cancer therapy[J]. Advanced Materials, 2018, 30(23):1800180
[45] Wang X Y, Li Y M, Li Q S, et al. Hyaluronic acid modification of RNase A and its intracellular delivery using lipid-like nanoparticles[J]. Journal of Controlled Release, 2017, 263:39-45.
[46] Yang R, Xu J, Xu L, et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination[J]. ACS Nano, 2018, 12(6):5121-5129.
[47] Qiao C, Yang J, Shen Q, et al. Traceable nanoparticles with dual targeting and ros response for rnai-based immunochemotherapy of intracranial glioblastoma treatment[J]. Advanced Materials, 2018, 30(18):1705054.
[48] Wang Y, Xie Y, Li J, et al. Tumor-penetrating nanoparticles for enhanced anticancer activity of combined photodynamic and hypoxia-activated therapy[J]. ACS Nano, 2017, 11(2):2227-2238.
[49] Xu X, Saw P E, Tao W, et al. ROS-responsive polyprodrug nanoparticles for triggered drug delivery and effective cancer therapy[J]. Advanced Materials, 2017, 29(33):201700141.
[50] Ahn J, Miura Y, Yamada N, et al. Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer[J]. Biomaterials, 2015, 39:23-30.
[51] Wang T, Wang D, Liu J, et al. Acidity-triggered ligand-presenting nanoparticles to overcome sequential drug delivery barriers to tumors[J]. Nano Letters, 2017, 17(9):5429-5436.
[52] Li D, Ma Y, Du J, et al. Tumor acidity/NIR controlled interaction of transformable nanoparticle with biological systems for cancer therapy[J]. Nano Letters, 2017, 17(5):2871-2878.
[53] Li J, Zhen X, Lyu Y, et al. Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics[J]. ACS Nano, 2018, 12(8):8520-8530.
[54] Fang R H, Hu C M J, Luk B T, et al. Cancer cell membranecoated nanoparticles for anticancer vaccination and drug delivery[J]. Nano Letters, 2014, 14(4):2181-2188.
[55] Hu C M J, Zhang L, Aryal S, et al. Erythrocyte membranecamouflaged polymeric nanoparticles as a biomimetic delivery platform[J]. PNAS, 2011, 108(27):10980-10985.
[56] Aizik G, Waiskopf N, Agbaria M, et al. Delivery of liposomal quantum dots via monocytes for imaging of inflamed tissue[J]. ACS Nano, 2017, 11(3):3038-3051.
[57] Lang T Q, Dong X Y, Huang Y, et al. Ly6C(hi) monocytes delivering ph-sensitive micelle loading paclitaxel improve targeting therapy of metastatic breast cancer[J]. Advanced Functional Materials, 2017, 27(26):1701093.
[58] He X Y, Cao H Q, Wang H, et al. Inflammatory monocytes loading protease-sensitive nanoparticles enable lung metastasis targeting and intelligent drug release for anti-metastasis therapy[J]. Nano Letters, 2017, 17(9):5546-5554.
[59] Chambers E, Mitragotri S. Long circulating nanoparticles via adhesion on red blood cells:Mechanism and extended circulation[J]. Experimental Biology and Medicine, 2007, 232(7):958-966.
[60] Sun H P, Su J H, Meng Q S, et al. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors[J]. Advanced Materials, 2016, 28(43):9581-9588.
[61] Cao H Q, Dan Z L, He X Y, et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer[J]. ACS Nano, 2016, 10(8):7738-7748.
